Rheumatology

Another recent study found that the risk of joint damage and gout flares were most important to patients when considering ULT discontinuation.

More patients also switched from combination therapy to monotherapy at any time in both analyzed database populations.

Around 20% of participants had ultrasound evidence of at least 1 active enthesitis, and 15.7% had ultrasound signs of at least 1 active synovitis at examination.

Each unit increase in TyG index was associated with 40% higher odds of gout.

A separate paper also found that the overall risk of serious infection was low in new users of targeted therapy.

Both treatment arms experienced significant improvements in measured parameters from baseline, although these were not all statistically significant.

A retrospective analysis compared data from the BE OPTIMAL and BE COMPLETE trials with data from pivotal trials of the IL-23–targeting therapies.

The study was not adequately powered to assess a significant association with cancer mortalities.

Adalimumab-aaty was FDA approved on May 23, 2023, and became commercially available in the US on July 2, 2023.

Similar trends were seen in study participants that transitioned from receiving placebo to bimekizumab after study week 16.

Adjusted analyses reveal a statistically significantly higher prescription medication cost in patients with RA compared to those without.

A new study using FDA's Sentinel System found no significant association between recombinant zoster vaccine and incident gout in adults aged 50+.

A new study found approximately 40% with osteoarthritis and 36.3% with RA screened positive for anxiety, depression, and fibromyalgia.

A new study revealed patients with chronic pain treated with opioid analgesics had a greater prevalence of opioid dependence, opioid use disorder, and aberrant behavior.

Medical experts engage in a discussion surrounding the treatment and management of patients diagnosed with psoriasis and psoriatic arthritis.

The repository corticotropin injection is designed to help patients manage their medication alongside a range of chronic and acute autoimmune and inflammatory conditions.

A study found the association between physical activity engagement and reduction in depression symptoms is moderated by pain.

Results from a Mendelian randomization analysis indicate type 1 diabetes significantly increases the likelihood of autoimmune conditions like rheumatoid arthritis and multiple sclerosis.

A review of the 20 novel drugs approved by the US Food and Drug Administration during the first half of 2024, with links to coverage from MJH Life Sciences publications.

A study presented at EULAR 2024 found anxiety, depression, and sleep disorders were significantly correlated to pain intensity.

Amanda Mixon, PA-C, discusses how rheumatic diseases may first present in skin, ocular or gastric symptoms.

EULAR 2024 data link maternal intake of over 252 grams of fish per week with higher risk of juvenile idiopathic arthritis in offspring, but causation is unclear.

A study from EULAR details the ability of the FIRST self-questionnaire to identify fibromyalgia in patients with rheumatoid arthritis.

A recent study provides some evidence of the ability to potentially reduce belimumab dose in a subset of patients with SLE.

Amanda Mixon, PA-C, discusses the need to better bridge the rheumatology and dermatology care teams due to overlapping diseases.

An analysis of the REALISTIC trial from EULAR 2024 details the effects of certolizumab pegol in rheumatoid arthritis based on rheumatoid factor levels and prior TNF inhibitor use.

The analysis of NHANES data revealed a dose-response association between weekly moderate-to-vigorous physical activity levels and hyperuricemia risk.

This analysis may require further research to determine whether other treatment-resistant depression or severe depression definitions are specifically associated with inflammatory joint disease.

Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.

As disparate representation in pivotal research impacts the outcomes of common diseases like lupus, clinicians and researchers alike are working to foster trust and collaboration with more patients of color.